Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Yen, Chia Jui ^a   Lin, Yih Jyh ^a   Yen, Chia Sheng ^b   Tsai, Hung Wen ^a   Tsai, Ting Fen ^c   Chang, Kwang Yu ^a,d   Huang, Wei Chien ^e   Lin, Pin Wen ^a   Chiang, Chi Wu ^a   Chang, Ting Tsung ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CD31 ANTIGEN; CELL PROTEIN; HEPATITIS B VIRUS X PROTEIN; I KAPPA B KINASE BETA; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

ADULT; AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

HEPATITIS B VIRUS; MAMMALIA; MUS MUSCULUS;

EID: 84864587705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041931     Document Type: Article

References (58)

1. Mazzanti R, Gramantieri L, Bolondi L, ((2008)) Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29,: 130--143.
2. Kulik LM, Mulcahy MF, Omary RA, Salem R, ((2007)) Emerging approaches in hepatocellular carcinoma. J Clin Gastroenterol 41,: 839--854.
3. Rougier P, Mitry E, Barbare J-C, Taieb J, ((2007)) Hepatocellular Carcinoma (HCC): An Update. Semin Oncol 34 Supplement 1: S12--S20.
4. Marotta F, Vangieri B, Cecere A, Gattoni A, ((2004)) The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 155,: 187--199.
5. Cougot D, Neuveut C, Buendia MA, ((2005)) HBV induced carcinogenesis. J Clin Virol 34 Suppl 1: S75--78.
6. Anzola M (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11,: 383--393.
7. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW, ((2007)) Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 31,: 1243--1248.
8. Kaido T, Uemoto S, ((2008)) Recent evidence in the treatment of small hepatocellular carcinoma. Hepatogastroenterology 55,: 1460--1462.
9. Lau WY, Lai EC, ((2008)) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7,: 237--257.
10. Yamazaki S, Takayama T, ((2008)) Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol 14,: 685--692.
11. Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, et al. ((2005)) Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat 12,: 635--641.
12. Dewantoro O, Gani RA, Akbar N, ((2006)) Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53. Acta Med Indones 38,: 154--159.
13. Park US, Su JJ, Ban KC, Qin L, Lee EH, et al. ((2000)) Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1. Gene 251,: 73--80.
14. Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R, ((2007)) Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 6,: 208--213.
15. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, et al. ((2003)) Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106,: 334--341.
16. Tommasi S, Pinto R, Pilato B, Paradiso A, ((2007)) Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des 13,: 3279--3287.
17. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. ((2006)) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46,: 249--279.
18. Kasai Y, Takeda S, Takagi H, ((1996)) Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin Surg Oncol 12,: 155--159.
19. Coussens LM, Werb Z, ((2002)) Inflammation and cancer. Nature 420,: 860--867.
20. Balkwill F, Mantovani A, ((2001)) Inflammation and cancer: back to Virchow? Lancet 357,: 539--545.
21. Lu H, Ouyang W, Huang C, ((2006)) Inflammation, a key event in cancer development. Mol Cancer Res 4,: 221--233.
22. Rollins BJ, ((2006)) Inflammatory chemokines in cancer growth and progression. Eur J Cancer 42,: 760--767.
23. Raman D, Baugher PJ, Thu YM, Richmond A, ((2007)) Role of chemokines in tumor growth. Cancer Lett 256,: 137--165.
24. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M, ((2004)) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6,: 297--305.
25. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. ((2004)) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118,: 285--296.
26. Clement JF, Meloche S, Servant MJ, ((2008)) The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 18,: 889--899.
27. Basseres DS, Baldwin AS, ((2006)) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25,: 6817--6830.
28. Li H, Lin X, ((2008)) Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41,: 1--8.
29. Scheidereit C, ((2006)) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25, 6: 685--6705.
30. Budhu A, Wang XW, ((2006)) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80,: 1197--1213.
31. Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, et al. ((2004)) Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res 64,: 7030--7038.
32. Biermer M, Puro R, Schneider RJ, ((2003)) Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 77,: 4033--4042.
33. Gish RG, Baron A, ((2008)) Hepatocellular carcinoma (HCC): current and evolving therapies. IDrugs 11,: 198--203.
34. Pang RW, Poon RT, ((2007)) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 Suppl 1: 30--44.
35. Aravalli RN, Steer CJ, Cressman EN, ((2008)) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48,: 2047--2063.
36. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. ((2007)) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130,: 440--455.
37. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, et al. ((2008)) Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 68,: 2632--2640.
38. Lee DF, Hung MC, ((2007)) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6,: 3011--3014.
39. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, et al. ((2007)) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46,: 840--848.
40. Bu X, Jia F, Wang W, Guo X, Wu M, et al. ((2007)) Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer 7,: 208.
41. Melegari M, Scaglioni PP, Wands JR, ((1998)) Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol. 72,: 1737--1743.
42. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, et al. ((2005)) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19,: 159--170.
43. Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, et al. ((2008)) Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res 68,: 2033--2042.
44. Grivennikov SI, Karin M, ((2010)) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20,: 65--71.
45. Guo SP, Wang WL, Zhai YQ, Zhao YL, ((2001)) Expression of nuclear factor-kappa B in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus. World J Gastroenterol 7,: 340--344.
46. Siddiqui A, Gaynor R, Srinivasan A, Mapoles J, Farr RW, ((1989)) Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 169,: 479--484.
47. Seto E, Mitchell PJ, Yen TS, ((1990)) Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 344,: 72--74.
48. Lucito R, Schneider RJ, ((1992)) Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol 66,: 983--991.
49. Lara-Pezzi E, Majano PL, Gomez-Gonzalo M, Garcia-Monzon C, Moreno-Otero R, et al. ((1998)) The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology 28,: 1013--1021.
50. Su F, Schneider RJ, ((1996)) Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 70,: 4558--4566.
51. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, et al. ((2004)) Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 10,: 4140--4149.
52. Zhou Y, Wang S, Ma JW, Lei Z, Zhu HF, et al. ((2010)) Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes. J Biol Chem 285,: 12159--12168.
53. Benn J, Schneider RJ, ((1994)) Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 91,: 10350--10354.
54. Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH, ((1993)) Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature. 361,: 742--745.
55. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, et al. ((2004)) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10,: 8421--8425.
56. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, et al. ((2007)) Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83,: 425--432.
57. Yoo YG, Cho S, Park S, Lee MO, ((2004)) The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett 577,: 121--126.
58. Yoo YG, Oh SH, Park ES, Cho H, Lee N, et al. ((2003)) Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 278,: 39076--39084.